Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Federal Reserve shifts to quarter-point rate rise but warns of more to come
    • ‘Hybrid identities’: why Germany is updating its citizenship rules
    • ECB set to raise rates despite fall in eurozone inflation
    • Italy to join forces with France in supplying air defences to Ukraine
    • Brussels urged to rein in Ukraine’s ‘unrealistic’ EU hopes
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Adani sell-off tops $90bn as share sale fails to ease crisis
      • ‘Extreme leverage’? Adani’s debt-driven expansion under scrutiny
      • Adani Enterprises calls off $2.4bn share sale
      • How First Abu Dhabi Bank pursued Standard Chartered and ‘opened Pandora’s box’
      • Perella Weinberg banker tied to insider trading probe found dead
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Live news updates from February 1: Fed lifts rates 0.25 points, Eurozone inflation slows sharply
      • Adani Enterprises calls off $2.4bn share sale
      • Perella Weinberg banker tied to insider trading probe found dead
      • US stocks jump after Fed announces smaller rate rise
      • Lebanon devalues official exchange rate by 90%
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • The Big Read
      • Lex
      • Obituaries
      • Letters
      Most Read
      • End the Fed ‘put’
      • The return of the ‘British disease’
      • When good economic news may not be good news
      • Conservatives are too keen on money to win the culture war
      • Conservatives are forced to face the economic case for net zero
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Shoshana Zuboff: ‘Privacy has been extinguished. It is now a zombie’
      • A new generation refuses to keep quiet on age discrimination at work
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • The secrets of the Mercedes-Benz Holy Halls
      • Alexa Chung on the unpolished appeal of Indie Sleaze
      • Why I’m only buying five new things in 2023
      • Whitechapel Gallery offers thrilling landmark show of female abstract artists — review
      • Episode 3 of ‘The Last of Us’ shows TV at its best
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Roche Holding AG

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Monday, 14 November, 2022
      Roche late-stage Alzheimer’s trials end in failure

      Two studies of antibody treatment gantenerumab fail to slow decline in people with early-stage disease

    • Tuesday, 18 October, 2022
      Roche’s sales of Covid drugs fall by $1bn

      Swiss pharma group says demand for coronavirus tests dropped as severity of virus ebbed

    • Thursday, 21 July, 2022
      Roche’s chief executive to step down and become chair

      Severin Schwan will be succeeded by Thomas Schinecker, head of drugmaker’s diagnostics unit

    • Monday, 25 April, 2022
      LexCoronavirus treatment
      Roche/diagnostics: Covid vaccine victory means test makers take a rest Premium content

      Do not dismiss the possibility of another upturn in the coronavirus testing market

    • Monday, 25 April, 2022
      Roche sales boosted by North American demand for Covid tests

      Swiss pharmaceuticals group expects revenue from coronavirus treatments will decline this year

    • Wednesday, 6 April, 2022
      LexPharmaceuticals sector
      Breast cancer: precision drugs make inroads against stubborn tumours Premium content

      New therapies replace a blunderbuss with a stiletto

    • Thursday, 4 November, 2021
      Novartis to sell its Roche stake worth $21bn

      Twenty-year shareholding had kept the two Swiss drugmakers closely linked

    • Thursday, 5 August, 2021
      Due Diligence
      SoftBank’s newfangled bet on a 125-year-old drugmaker Premium content

      Plus, inside the cut-throat game of private equity and European football

    • Wednesday, 4 August, 2021
      LexPharmaceuticals sector
      SoftBank/Roche: Northstar reorients to embrace drug development Premium content

      The Swiss company and Japanese tech investor both have a taste for big data and disruption

    • Wednesday, 4 August, 2021
      SoftBank Group Corp
      SoftBank acquires $5bn stake in Swiss drugmaker Roche

      Deal struck through unit of Japanese technology group that was behind ‘Nasdaq whale’ trade

    • Monday, 5 July, 2021
      News in-depthPharmaceuticals sector
      Approval of Biogen Alzheimer’s drug reignites ‘amyloid’ debate

      Hypothesis that brain plaques cause disease viewed with scepticism by some scientists

    • Thursday, 13 May, 2021
      Covid-19 vaccines
      Roche chief compares waiving vaccine patents to East German nationalisation

      Severin Schwan believes proposal is ‘counterproductive’ and will not solve supply shortages

    • Wednesday, 21 April, 2021
      Covid-19 test demand boosts Roche

      Swiss pharmaceutical company reports 55% jump in diagnostic sales

    • Friday, 2 April, 2021
      LexPharmaceuticals sector
      Roche/Novartis: rivals play king of the pill Premium content

      The pharmaceuticals are battling in similar markets, but their share price performances have diverged

    • Thursday, 15 October, 2020
      Roche says broader tests needed for second Covid wave

      ‘If you look at the curves going up everywhere, relying on PCR alone will not work’

    • Tuesday, 6 October, 2020
      Coronavirus treatment
      NHS labs hit by shortage of vital kit and chemicals for Covid tests

      Supplier Roche warns of disruption as infections rise sharply

    • Wednesday, 22 July, 2020
      ExplainerCoronavirus pandemic
      Test, test, test — but what can America do about the delays?

      Patients in the US are waiting more than a week for results, by which time it’s probably too late

    • Wednesday, 24 June, 2020
      Due Diligence
      Banks: back to the office Premium content

      The question is how a return to work can be made safe without a vaccine?

    • Tuesday, 23 June, 2020
      Inside BusinessKana Inagaki
      A Swiss-Japanese alliance that has thrived in the crisis

      Roche and Chugai provide lessons on how to keep a cross-border partnership intact

    • Tuesday, 16 June, 2020
      Coronavirus pandemic
      UK antibody test access stokes frustration and confusion

      Consumers and doctors eager to understand who has immunity face uncertainty over testing and reliability

    • Thursday, 21 May, 2020
      Coronavirus pandemic
      Free NHS antibody tests on way after Roche and Abbott Labs deals

      And trials of 20-minute swab test to determine coronavirus infection will start next week

    • Friday, 15 May, 2020
      Coronavirus pandemic
      Abbott joins Roche in winning UK approval for virus antibody test

      Public Health England gives green light to second diagnostic kit to detect past infection and potential immunity

    • Wednesday, 13 May, 2020
      Public Health England
      Public Health England gives green light to coronavirus antibody test

      Approval for Roche project paves way for checks on who has had disease and who has potential immunity

    • Friday, 24 April, 2020
      News in-depthSeverin Schwan
      Roche boss who says bitter pill of truth is only way to build trust  

      Severin Schwan unapologetic for outspoken criticism of state responses to coronavirus

    • Wednesday, 22 April, 2020
      Coronavirus pandemic
      Roche chief criticises under-investment in UK healthcare

      Lack of spending means Britain trails behind in coronavirus testing, says Swiss group’s head

    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition
    • Top sections
    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • The Big Read
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports
    • FT recommends
    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • FTfm
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In